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Enveloped viruses: A common mode of membrane fusion?
Frederick M. Hughson
Viruses use elaborate stratagems to enter cells. The
HIV-1 envelope glycoprotein, which mediates both
attachment and membrane fusion, has grudgingly
begun to yield high-resolution structural information
that suggests mechanistic similarities with the
hemagglutinin protein of influenza virus.
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Enveloped viruses such as human immunodeficiency
virus-1 (HIV-1) use specialized surface glycoproteins to
enter host cells. These envelope proteins serve a dual
purpose, mediating both cell binding and membrane
fusion. Initially, they attach virus to cells by binding to
cell-surface receptors. Subsequently, they promote fusion
between viral and cellular membranes; indeed, the
influenza virus hemagglutinin is perhaps the best-charac-
terized membrane fusion protein (for reviews see [1,2]).
Efforts to understand how these proteins work have been
aided in recent years by the determination of several viral
fusion protein structures (Figure 1) [3–6]. Two recent
crystal structures [7,8] of core fragments of the HIV-1
transmembrane glycoprotein gp41 show striking similari-
ties to several other viral fusion proteins, including hemag-
glutinin. An important challenge for the future is to design
experiments that test and extend mechanistic ideas
derived from these structures.
The HIV and influenza fusion proteins, despite the lack
of detectable sequence homology, share several general
structural features [1,9]. Both are homotrimers; the sub-
units are synthesized as single polypeptide chains that are
subsequently cleaved, yielding, in the case of HIV-1,
gp120 and gp41, and in the case of influenza, HA1 and
HA2. The smaller carboxy-terminal fragment — gp41 or
HA2 — remains anchored in the viral membrane and
seems to play a direct role in membrane fusion. In particu-
lar, the hydrophobic stretch of residues at the amino-ter-
minus of the newly-created gp41 or HA2 chain appears to
insert into the cell membrane prior to fusion, and is called
the ‘fusion peptide’. Between the fusion peptide
sequence and the transmembrane domain lie regions com-
posed of heptad repeats of hydrophobic residues that are
predicted to form α-helical coiled coils [10].
Figure 1
Comparative anatomy of trimeric viral fusion
proteins. The individual subunits are colored
red, green and blue. (a) HIV-1 gp41 [8]. The
first twenty-nine gp41 residues, including the
fusion peptide, are replaced by a modified
GCN4 sequence that by itself forms a trimeric
coiled coil [23]. The other gp41 structure [7]
includes gp41 residues 35–70 and 117–150
and agrees closely with that shown here. 
(b) Moloney murine leukemia virus
transmembrane subunit [6]. (c) Low pH-
induced structure of influenza virus HA2
subunit [4]. (d) Neutral pH structure of
influenza virus HA2 subunit [3]. The HA1
subunits are omitted for clarity. (Reproduced
with permission from [8].)
Influenza virus hemagglutinin, solubilized by removal of
its transmembrane anchor, was the first viral glycoprotein
to have its atomic structure determined by X-ray crystal-
lography [3]. In the structure, the three HA2 chains (analo-
gous to gp41) are seen to form a trimeric ‘stem’ built
around three long central α-helices. The HA1 chains (anal-
ogous to gp120) contribute somewhat to the stem, but the
main central portion of each HA1 chain forms a globular
‘head’ domain that sits atop the stem, distal to the viral
membrane. Not surprisingly, each of the three globular
head domains has a binding site for sialic acid, the cellular
receptor [11].
The fusion peptide sequences at the amino-termini of the
HA2 chains are tucked away into the interior of the stem
domain (Figure 1d), a puzzling location given the evi-
dence that they interact with the cell membrane prior to
fusion [12]. The resolution to this conundrum required a
decade of work, during which it was realized that hemag-
glutinin undergoes a dramatic conformational change after
a virus particle binds to a cell and is internalized by recep-
tor-mediated endocytosis [1]. This conformational change,
triggered by the low pH of the endosome, leads to the
fusion of viral and endosomal membranes, releasing the
viral nucleocapsid into the cytoplasm of the cell.
Purified hemagglutinin also changes conformation upon
exposure to pH 5–6, presumably adopting the ‘fusogenic’
conformation. Although it has not proved possible to crys-
tallize low-pH-treated intact hemagglutinin, the crystal
structures of two relatively large proteolytic fragments
have been determined. One fragment, comprising most of
HA1 (complexed with a neutralizing antibody), displays no
significant change relative to the initial, neutral-pH struc-
ture [13]. This result implies that the globular fold of the
head domains is not pH-sensitive, although there is evi-
dence that the head domains move as units during the
conformational change [2]. 
The other proteolytic fragment of the low-pH-treated
hemagglutinin for which structural information is available
is a trimeric piece containing much of the HA2 chain
(Figure 1c) [4]. To render this fragment water-soluble,
both the carboxy-terminal transmembrane anchor and the
amino-terminal hydrophobic fusion peptide sequence
were proteolytically removed. Compared with the neutral
pH structure, the low-pH-treated HA2 chain is seen to
have undergone a dramatic conformational change (Figure
1c,d). The core of the structure, composed of a thirty-
residue, triple-stranded coiled coil, remains unchanged. In
the neutral pH structure, the region amino-terminal to this
coiled coil forms an extended loop preceded by an α helix
that packs against — and antiparallel to — the coiled coil.
In the low-pH-structure, however, this hairpin-like
arrangement has straightened out to form a single coiled
coil, sixty-six residues long. Although amino-terminal
residues including the fusion peptide were proteolytically
removed, the extension of the coiled coil would relocate
these residues about 100 Å to the ‘top’ of the molecule, in
position to insert into the target cell membrane.
The straightening-out of one ‘helix hairpin’ is accompa-
nied by the emergence of a different one. This second
aspect of the low-pH-induced conformational change relo-
cates and rearranges structures at the viral membrane end
of the neutral pH hemagglutinin [4], affecting the confor-
mation of the carboxy-terminal part of the HA2 chain
between the invariant coiled coil segment and the trans-
membrane anchor. In the low-pH-induced conformation,
the residues immediately following the trimeric coiled coil
jack-knife up to pack against it, forming an antiparallel
helix that appears quite securely positioned by an exten-
sive hydrophobic interface. This helix is followed by a
meandering set of structural elements that, at least as
judged by crystallographic B factors, do not seem as firm,
and the course of the polypeptide chain near the trans-
membrane anchor is not discernible. Nonetheless, it can
be seen that the net effect of the low-pH-induced confor-
mational change is to bring the last visible residue in the
polypeptide chain (residue 162) rather close (~30 Å) to the
first (residue 40) (Figure 1c). This second aspect of the
‘fusogenic’ structure has, perhaps, been somewhat under-
emphasized; however, its forceful reappearance in the
new gp41 structures seems to call for a revaluation of its
significance (see  below).
Unlike influenza virus, HIV-1 enters a cell at its surface, in
a pH-independent manner. Like influenza virus, however,
activation of the HIV-1 viral fusion protein requires
conformational changes, in this case triggered by binding
to the cellular receptor CD4 and subsequently to a co-
receptor [14–16]. Several HIV-1 fusion cofactors have
recently been found to be members of the chemokine
receptor family. These conformational changes have not
been characterized in detail as, until recently, the HIV-1
envelope protein had rebuffed all attempts at obtaining
diffraction-quality crystals. Now, however, two groups
have determined the crystal structures of slightly different
core fragments of the HIV-1 gp41 ectodomain (the portion
exterior to the viral membrane), apparently in the fuso-
genic conformation [7,8].
These new structures represent a relatively small (~10%)
but important part of the gp120–gp41 complex — the stable
core of the gp41 ectodomain. Kim and coworkers [17] had
previously found that the bacterially-expressed gp41
ectodomain, though aggregated, could be digested with
non-specific proteases to yield a defined, stable, soluble
core domain. This domain is composed of two peptides
separated by thirty-three residues in the gp41 sequence:
one peptide (N-51; named for its length), was derived from
an amino-terminal region adjacent to the fusion peptide,
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whereas the second peptide (C-43) was derived from
sequences nearer the transmembrane domain. 
Equilibrium ultracentrifugation revealed that this stable
core domain has three N-51 peptides and three C-43
peptides; circular dichroism (CD) suggested that the
domain is essentially 100% α-helical. Based on these and
other results, Kim and coworkers [17] proposed a model for
the core domain, in which the three N-51 peptides form a
triple-stranded α-helical coiled coil in the center, while the
three C-43 peptides form helices that pack in an antiparal-
lel fashion into the grooves between adjacent N-51 helices.
This model was bolstered by very similar results for the
simian immunodeficiency virus (SIV) gp41 protein that led
to an analogous model [18].
In the models for both HIV-1 and SIV gp41 [17,18], the
conserved, mostly hydrophobic residues at the a and d
heptad positions of the N helices pack together at the core
of a three-stranded coiled coil. The e and g heptad posi-
tions are also conserved and rather hydrophobic, creating
non-polar grooves between adjacent N helices on the
outer surface of the coiled coil. According to the model,
the C helices pack against the outside of the coiled coil by
projecting their hydrophobic a and d residues into this
non-polar groove. The recent structures [7,8] represent
the gp41 core domain reconstituted from peptides corre-
sponding to similar portions of the N and C helices.
Although some interesting subtleties involving shifts in
the heptad register of the outer helices were not antici-
pated [8], the crystal structures show that the HIV-1
model [17] — and presumably also the SIV model [18] —
are essentially correct.
The structure of the HIV gp41 core domain (Figure 1a) has
striking similarities to the low-pH-induced HA2 structure
discussed above [7,8]. In both cases, sequences adjacent to
the amino-terminal fusion peptide form a triple-stranded
coiled coil buttressed by antiparallel helices derived from
more carboxy-terminal sequences. The crystal structure of a
shorter fragment of the Moloney murine leukemia virus
transmembrane protein (MMLV-TM) also revealed a
central three-stranded coiled coil (Figure 1b) [6]. In this
case, the structure of the region corresponding to the but-
tressing helix has not yet been determined. Nonetheless,
longer fragments of MMLV-TM including this region have
been characterized by CD, which revealed a helix content
consistent with the presence of a buttressing helix [19].
The HA2 structure was the first to imply that the fusion
peptide and transmembrane domain might be close
together at the same end of the extended ‘fusogenic’ con-
formation triggered by low pH (see above), a possibility
further supported by biochemical experiments using
membrane-embedded HA2 [20]. This feature has now
reappeared in the structures of two different retroviral
fusion proteins, gp41 and MMLV-TM. During and after
fusion, therefore, it seems likely (and sensible) that the
fusion protein segments embedded in the two fusing
membranes come quite near to one another (Figure 2) [8].
To accomplish this, hemagglutinin — and perhaps the
retroviral fusion proteins — undergoes at least two concep-
tually distinguishable conformational rearrangements [2].
In the first rearrangement, the coiled coil extends, pro-
pelling the fusion peptide toward the cellular membrane
and away from the transmembrane domain that anchors
the protein in the viral membrane. In the second
rearrangement, a further refolding of the ectodomain, this
time involving a more carboxy-terminal region, brings the
fusion peptide back into the vicinity of the transmem-
brane domain. These rearrangements seem likely to be
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Model for the membrane fusion mechanism of viral envelope proteins
[8]. Conformational changes expose the fusion peptide, which
becomes embedded in the cellular membrane. Further structural
rearrangements in the protein accompany the close approach of the
viral and cellular membranes, bringing the transmembrane anchor and
fusion peptide into relative proximity, where they remain after fusion is
completed. Cellular receptors are omitted for clarity.
sequential, as before the first rearrangement the ‘docking
site’ for the carboxy-terminal region against the coiled coil
is blocked by the fusion peptide and adjacent sequences.
An intriguing possibility, consistent with the known struc-
tures, is that this second rearrangement could accompany
close apposition of the two membranes [4,8].
Assuming that the features now visualized in three differ-
ent fusion proteins represent the fusogenic conformation
accurately, and that the two membranes are not grossly
deformed during apposition, then there is seemingly no
alternative to a model in which the fusion proteins, which
are tall and skinny, lie down as they become sandwiched
between the approaching bilayers (Figure 2). This process
would be facilitated by the flexibility that appears to char-
acterize the region of the ectodomain closest to the viral
membrane [4], presumably allowing the entire trimer to
bend readily with respect to the membrane. Such a model
is the distant descendent of much earlier ones based on a
simpler assumption: that the fusion peptide, although it
becomes exposed by the activating conformational
change, remains basically in the same place. Were this the
case, the fusion peptide, as it is in native hemagglutinin,
would be relatively near the transmembrane domain. Iron-
ically, the emerging new model envisions a highly
dynamic molecule in which the fusion peptide is ejected
and moves over a great distance, after which the protein
doubles up again to bring the fusion peptide back into the
vicinity of the transmembrane domain.
Although this model has significant experimental support
in the case of hemagglutinin, it is less clear that gp41
undergoes such extensive molecular gymnastics. In partic-
ular, it is not known whether the central coiled coil is
extended by the conformational change or exists at full
length throughout the lifetime of the molecule, protected
from premature exposure by interactions with the gp120
subunit. Perhaps the intimacy of the HIV-1 envelope
protein’s sequential interactions with CD4 and a seven-
transmembrane-helix chemokine receptor [15,16] obviates
the need for the gp41 subunit to harpoon the cell mem-
brane in such a dramatic way. But it remains possible that
the gp41 coiled coil is formed or extended during the
receptor/coreceptor-induced conformational change [7,8].
At present, though, the element of the hemagglutinin con-
formational change that seems most likely to be emulated
by the retroviral proteins is the formation of an antiparallel
structure that could serve to bring the fusion peptide and
transmembrane domain into proximity (Figures 1,2).
Strong, albeit indirect, evidence suggests that this antiparal-
lel structure does not preexist in the unactivated gp41
protein, but that its formation is required for fusion activity.
Peptides corresponding to regions within each helical
segment are relatively potent inhibitors of fusion and entry,
with the C peptide significantly more potent (effectively
inhibiting HIV-1-mediated cell–cell fusion and viral infec-
tion at nanomolar concentrations) [17,21,22]. In light of the
gp41 core structure and the rearrangements seen in HA2, it
seems plausible that these peptides work by interfering
with the interhelical interactions between the N and C
helices within gp41 [17,22]. Binding of peptides to the com-
plementary helix within gp41 would, therefore, exert a
dominant-negative effect on fusion.
These peptide experiments also suggest that blocking
fusion protein activation by interfering with the associa-
tion of N and C helices could be an effective strategy for
drugs directed against AIDS. The gp41 structure provides
a rational basis for designing small molecule inhibitors of
helix association [7,8]. In particular, a deep, conserved
pocket on the surface of the amino-terminal helix bundle
that accommodates two tryptophan residues from the C
helix is a promising target for the design of small mole-
cules that might block the formation of the antiparallel
structure [7]. If, in fact, the folding of buttressing helices
to form a six-helix bundle turns out to be a common
feature in viral fusion protein activation, the potential for
exploiting this feature in developing new drugs against
HIV-1 and other viruses will be even greater.
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